Beijing Strong Biotechnologies Inc
SZSE:300406
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Beijing Strong Biotechnologies Inc
Note Receivable
Beijing Strong Biotechnologies Inc
Note Receivable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Note Receivable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Beijing Strong Biotechnologies Inc
SZSE:300406
|
Note Receivable
¥4.2m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Note Receivable
¥83.7m
|
CAGR 3-Years
18%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
Note Receivable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
RemeGen Co Ltd
SSE:688331
|
Note Receivable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Note Receivable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
|
Note Receivable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Beijing Strong Biotechnologies Inc
Glance View
Beijing Strong Biotechnologies Inc. has carved a niche in the dynamic landscape of medical diagnostics and biotechnology, establishing itself as a prominent player in the industry. Founded in the bustling heart of China, the company has diligently pursued the development and commercialization of in vitro diagnostic reagents and instruments. Their journey began with a vision to enhance the precision and efficiency of diagnostic procedures, quickly progressing towards the production of advanced biochemical diagnostic products. Utilizing cutting-edge technology and rigorous quality control, Beijing Strong Biotechnologies ensures their offerings meet the ever-growing demands of the healthcare sector both domestically and internationally. The company's revenue model is primarily built around the sales of its diagnostic products, which include an extensive range of reagents and testing kits utilized in hospitals and laboratories around the world. As healthcare providers continually seek to improve the accuracy and speed of patient diagnoses, Beijing Strong Biotechnologies stands to benefit from this enduring trend. Their portfolio is diversified, catering not only to a spectrum of routine testing needs but also tapping into specialized segments that command premium pricing due to their complexity and critical application. By innovating and continually refining their product lines, the company ensures a strong market presence and maintains steady growth within the global arena.
See Also
What is Beijing Strong Biotechnologies Inc's Note Receivable?
Note Receivable
4.2m
CNY
Based on the financial report for Sep 30, 2025, Beijing Strong Biotechnologies Inc's Note Receivable amounts to 4.2m CNY.
What is Beijing Strong Biotechnologies Inc's Note Receivable growth rate?
Note Receivable CAGR 5Y
-28%
Over the last year, the Note Receivable growth was -66%. The average annual Note Receivable growth rates for Beijing Strong Biotechnologies Inc have been -36% over the past three years , -28% over the past five years .